Loading
Jupiter Neurosciences, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Silva Alison D., was filed 03 Jul 2025.
Jupiter Neurosciences, Inc.: what insiders have been doing
Every trade that managers of Jupiter Neurosciences, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Health Care sector. 5 insiders have disclosed 8 filings since 22 October 2025.
The filings describe grants, exercises and other transfers rather than trades on the open market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
Insider buying of Jupiter Neurosciences, Inc. has been absent for the past year.
For context, the typical company on the same exchange (median of 5,462 companies) published 28 filings over the same period, against 8 filings here. Over the whole record (from 2025), the tally stands at 20 purchases and no sales. The 10-K for the year ended 31 December 2025 shows 21,796 USD of revenue and -8.6 m USD of net income.
For comparison within the same sector, see the insider buying recorded at Xenon Pharmaceuticals Inc. and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
34
Thresholds
n/a
Buy Volume
€11,899
20 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleAlison D. Silva11 buys
Christer Rosen9 buys
Since the insiders bought
- -85.0%Entry US$110.25 · Close at T+365 US$16.58
- -85.0%Entry US$110.25 · Close at T+365 US$16.58
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.80
Analyst consensus
Income statement
RevenueUS$21.8k
Gross profitUS$17.6k81% margin
EBITDA-US$8.6M-39360% margin
Net income-US$8.6M-39662.8% margin
Balance sheet & cash
Market capUS$3.7M
Total debtUS$5.3M
Free Cash Flow-US$5.4M
Profitability & ownership
ROE-1888.7%
ROA-159.6%
% insiders30.0%
% institutions2.2%
Last declaration on 13 July 2026
Declarations34 total
96,608 sharesCommon StockSEC:0001493152-26-033016:1
82,875 sharesCommon StockSEC:0001493152-26-033017:0
164,553 sharesCommon StockSEC:0001493152-26-033016:0
389,793 sharesCommon StockSEC:0001493152-26-033015:0
399,402 sharesCommon StockSEC:0001493152-26-033015:1
95,550 sharesCommon StockSEC:0001493152-26-033014:0
85,800 sharesCommon StockSEC:0001493152-26-033013:0
225,000 sharesCommon StockSEC:0001493152-26-033015:2
66,293 shares0Common StockSEC:0001641172-25-018070:0
250 shares@ US$1.03Common StockSEC:0001641172-25-017894:1
Canonical exit: 29 Sept 2025 (T+90)
3,100 shares@ US$1.02Common StockSEC:0001641172-25-017750:1
Canonical exit: 29 Sept 2025 (T+90)
250 shares@ US$1.0263100.0% of flowCommon StockSEC:0001641172-25-017894:0
Canonical exit: 29 Sept 2025 (T+90)
500 shares@ US$1.01100.0% of flowCommon StockSEC:0001641172-25-017750:0
Canonical exit: 29 Sept 2025 (T+90)
1,450 shares@ US$1.02Common StockSEC:0001641172-25-017416:5
Canonical exit: 28 Sept 2025 (T+90)
700 shares@ US$1.03Common StockSEC:0001641172-25-017416:6
Canonical exit: 28 Sept 2025 (T+90)
1,500 shares@ US$1.04Common StockSEC:0001641172-25-017416:7
Canonical exit: 28 Sept 2025 (T+90)
1,000 shares@ US$1.05Common StockSEC:0001641172-25-017416:8
Canonical exit: 28 Sept 2025 (T+90)
250 shares@ US$1.00Common StockSEC:0001641172-25-017417:1
Canonical exit: 25 Sept 2025 (T+90)
100 shares@ US$1.04Common StockSEC:0001641172-25-017417:2
Canonical exit: 25 Sept 2025 (T+90)
250 shares@ US$1.04Common StockSEC:0001641172-25-017417:3
Canonical exit: 25 Sept 2025 (T+90)
250 shares@ US$1.05Common StockSEC:0001641172-25-017417:4
Canonical exit: 25 Sept 2025 (T+90)
100 shares@ US$1.02Common StockSEC:0001641172-25-017417:5
Canonical exit: 28 Sept 2025 (T+90)
250 shares@ US$1.02Common StockSEC:0001641172-25-017417:6
Canonical exit: 28 Sept 2025 (T+90)
250 shares@ US$1.03Common StockSEC:0001641172-25-017417:7
Canonical exit: 28 Sept 2025 (T+90)
250 shares@ US$1.04Common StockSEC:0001641172-25-017417:8
Canonical exit: 28 Sept 2025 (T+90)
25 of 34 declarations
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences, Inc. is a company focused on developing innovative treatments for neurological disorders. It is listed on the XNAS market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
